CAR T-Cell Therapy Against NHL and CLL: Current and Emerging Clinical Trial Evidence

Commentary on current molecular testing and biomarker-guided care in NSCLC, from Clinical Care Options (CCO)

Todd M. Bauer, MD Sandip P. Patel, MD Joshua Sabari, MD Released: May 26, 2022

Expert case-based text module on managing toxicities with BCL-2 and PI3K inhibitors in CLL, from Clinical Care Options (CCO)

Nichole Fisher, RN, BSN Nicole Lamanna, MD Anthony Perissinotti, PharmD, BCOP Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: May 19, 2022 Expired: May 18, 2023

Experts review key data for multiple myeloma at the 2021 hematology annual meeting, from Clinical Care Options (CCO)

Shaji K. Kumar, MD Sagar Lonial, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: May 12, 2022 Expired: May 11, 2023

Clinical Care Options (CCO): Expert review of key data in MDS and MPN from the 2021 ASH annual meeting

Amy E. DeZern, MD, MHS Srdan Verstovsek, MD, PhD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: May 11, 2022 Expired: May 10, 2023